Three analysts set a PLN 86.83 target for Captor Therapeutics stock
Published on 10/17/2026 at 22:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and trading date
- Investing.com listed a PLN 86.83 12-month consensus target from three analysts on October 15, 2026.
- The consensus target stands 52.33 percent above Captor Therapeutics stock's last Warsaw price.
- Captor Therapeutics stock last stood at PLN 57.00 at 4:59 p.m. CEST on October 16, 2026, down 2.40 percent versus the Warsaw prior close.
- Captor Therapeutics is scheduled to publish third-quarter results on November 19, 2026.
Three analysts set a PLN 86.83 12-month target for Captor Therapeutics. On October 15, 2026, Investing.com listed the consensus, putting it 52.33 percent above the last Warsaw price of PLN 57.00. The stock last stood at PLN 57.00 in Warsaw on October 16, 2026 at 4:59 p.m. CEST, down 2.40 percent versus the prior close of PLN 58.40.
Analyst target reaches 52.33 percent
The target spread is the clearest valuation reference in the current market picture. Investing.com showed a low analyst target of PLN 67.00 and a high of PLN 110.00, with three analysts included in the 12-month survey. The average target therefore sits PLN 29.83 above the last Warsaw price, a gap of 52.33 percent calculated from PLN 57.00.
Price position on Warsaw
Captor Therapeutics finished the latest completed Warsaw session at PLN 57.00, compared with a 52-week low of PLN 40.10 and a 52-week high of PLN 89.20. The price was 42.14 percent above the low and 36.10 percent below the high. Trading volume reached 20,526 shares against an average of 4,590 shares in the quoted session data.
The latest move was weaker than the two selected Polish biotechnology comparisons. Ryvu Therapeutics gained 3.44 percent to a market capitalization of PLN 417.1 million, while Molecure fell 0.63 percent and had a market capitalization of PLN 156.3 million. Captor Therapeutics had a market capitalization of PLN 361.0 million and fell 2.40 percent.
Valuation and next results
The next dated company event is the third-quarter reporting date of November 19, 2026, according to Zonebourse. That date gives the market a defined checkpoint after the first-half reporting cycle. The same calendar identifies Captor Therapeutics as listed on the Warsaw Stock Exchange under ticker CTX.
Comparison with peers
Captor Therapeutics (Warsaw, PLN): minus 2.40 percent, market capitalization PLN 361.0 million.
Ryvu Therapeutics (Warsaw, PLN): plus 3.44 percent, market capitalization PLN 417.1 million.
Molecure (Warsaw, PLN): minus 0.63 percent, market capitalization PLN 156.3 million.
Trading level and calendar
The latest price leaves Captor Therapeutics below the midpoint of its PLN 40.10 to PLN 89.20 52-week range. The upcoming November 19 reporting date and the PLN 86.83 analyst consensus provide the two next reference points for the stock.
Market context: Market report WIG 20.
